forbes.com · 17 jun

Ozempic Linked To Lower Risk Of Violence In New Study

The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New Jersey Gun Violence Research Center at the Rutgers School of Public Health, said it is important to continue studying the impact of GLP-1 medications on users' behavior and public safety as the medications become more widespread.

fool.com · 12 jun

Twist Bioscience Director Sold 12,000 Shares. Here's What That Means for Investors.

12,000 shares were exercised from options and sold for a total of ~$673,000 on May 12, 2026. All shares were transacted directly via option exercise and immediate sale; no indirect entities or gifts were involved.

zacks.com · 12 jun

Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?

Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

fool.com · 6 jun

Twist Bioscience's Chief Legal Officer Sold Over 14,000 Company Shares. What Does That Mean for Investors?

This synthetic biology innovator, known for its DNA-based solutions, reported a notable insider sale amid a year of strong share gains.

fool.com · 5 jun

Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech

Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.

fool.com · 4 jun

Twist Biosciences' (TWST) CEO Sold 16,000 Shares for $1.1 Million

This synthetic biology firm, known for silicon-based DNA synthesis, reported a notable insider sale following strong one-year share gains.

zacks.com · 2 jun

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.

businesswire.com · 27 may

Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist Bioscience will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 10:00 am Central Time in Chicago, Illinois. The presentation will be webcast live and can be accessed by visiting the “Investor Calendar”.